Immunocompatible elastomer with increased resistance to the foreign body response

Xianchi Zhou, Zhouyu Lu, Wenzhong Cao, Zihao Zhu, Yifeng Chen, Yanwen Ni, Zuolong Liu, Fan Jia, Yang Ye, Haijie Han, Ke Yao, Weifeng Liu, Youxiang Wang, Jian Ji and Peng Zhang ()
Additional contact information
Xianchi Zhou: Zhejiang University School of Medicine
Zhouyu Lu: Zhejiang University
Wenzhong Cao: Zhejiang University
Zihao Zhu: Zhejiang University
Yifeng Chen: Zhejiang University
Yanwen Ni: Zhejiang University
Zuolong Liu: Zhejiang University School of Medicine
Fan Jia: Zhejiang University
Yang Ye: Zhejiang University
Haijie Han: Zhejiang University
Ke Yao: Zhejiang University
Weifeng Liu: Zhejiang University
Youxiang Wang: Zhejiang University
Jian Ji: Zhejiang University School of Medicine
Peng Zhang: Zhejiang University School of Medicine

Nature Communications, 2024, vol. 15, issue 1, 1-17

Abstract: Abstract Polymeric elastomers are extensively employed to fabricate implantable medical devices. However, implantation of the elastomers can induce a strong immune rejection known as the foreign body response (FBR), diminishing their efficacy. Herein, we present a group of immunocompatible elastomers, termed easy-to-synthesize vinyl-based anti-FBR dense elastomers (EVADE). EVADE materials effectively suppress the inflammation and capsule formation in subcutaneous models of rodents and non-human primates for at least one year and two months, respectively. Implantation of EVADE materials significantly reduces the expression of inflammation-related proteins S100A8/A9 in adjacent tissues compared to polydimethylsiloxane. We also show that inhibition or knockout of S100A8/A9 leads to substantial attenuation of fibrosis in mice, suggesting a target for fibrosis inhibition. Continuous subcutaneous insulin infusion (CSII) catheters constructed from EVADE elastomers demonstrate significantly improved longevity and performance compared to commercial catheters. The EVADE materials reported here may enhance and extend function in various medical devices by resisting the local immune responses.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-52023-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-52023-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-52023-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().